Abstract

Accumulating evidence supports the early involvement of monocyte/macrophage recruitment to activated endothelial cells by leukocyte adhesion molecules during atherogenesis. CD40 and its ligand CD40L are highly expressed in vascular endothelial cells, but its impact on monocyte adhesion and the related molecular mechanisms are not fully understood. The present study was designed to evaluate the direct effect of CD40L on monocytic cell adhesion and gain mechanistic insight into the signaling coupling CD40L function to the proinflammatory response. Exposure of cultured human aortic endothelial cells (HAECs) to clinically relevant concentrations of CD40L (20 to 80 ng/mL) dose-dependently increased human monocytic THP-1 cells to adhere to them under static condition. CD40L treatment induced the expression of vascular cell adhesion molecule-1 (VCAM-1) mRNA and protein expression in HAECs. Furthermore, exposure of HAECs to CD40L robustly increased the activation of protein kinase C beta (PKCβ) in ECs. A selective inhibitor of PKCβ prevented the rise in VCAM-1 and THP-1 cell adhesion to ECs. Moreover, stimulation of ECs to CD40L induced nuclear factor-κB (NF-κB) activation. PKCβ inhibition abolished CD40L-induced NF-κB activation, and NF-κB inhibition reduced expression of VCAM-1, each resulting in reduced THP-1 cell adhesion. Our findings provide the evidence that CD40L increases VCAM-1 expression in ECs by activating PKCβ and NF-κB, suggesting a novel mechanism for EC activation. Finally, administration of CD40L resulted in PKCβ activation, increased VCAM-1 expression and activated monocytes adhesiveness to HAECs, processes attenuated by PKCβ inhibitor. Therefore, CD40L may contribute directly to atherogenesis by activating ECs and recruiting monocytes to them.

Highlights

  • Atherosclerosis is a complex pathological process that possesses many features of chronic inflammation and is considered an immunoinflammatory disease [1,2]

  • The adhesion of circulating monocytes to endothelial cells (ECs) monolayer, which is regulated by multiple cell adhesion molecules, such as selectins, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 (VCAM-1), contributes importantly to the inflammatory aspects of the progression of atherogenesis [3,4]

  • To investigate the underlying mechanism of CD40L-mediated inhibition of monocyte adhesion, we explore the role of CD40L on VCAM-1 expression in human aortic endothelial cells (HAECs)

Read more

Summary

Introduction

Atherosclerosis is a complex pathological process that possesses many features of chronic inflammation and is considered an immunoinflammatory disease [1,2]. Modulation of monocyte adhesion to the vascular endothelium is regarded as an important therapeutic target for the prevention and treatment of atherosclerosis. CD40 and CD40L are expressed on endothelial cells, vascular smooth muscle cells, mononuclear cells, and platelets, and CD40-CD40L interaction has been shown to exhibit proinflammatory and proatherogenic effects in vitro and in vivo [8,9]. In addition to the cell-associated form, CD40L exists in a soluble, biologically active form (sCD40L), which has similar proinflammatory effects on vascular cells. CD40L has been suggested as a potential therapeutic target to modulate vascular inflammation and possibly influence cardiovascular risks. The underlying molecular mechanism by which CD40L enhances vascular inflammation and atherogenesis is not fully understood

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call